GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE

 natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5 , 2026, in Toronto, Ontario.

Format: Presentation, panel discussion and 1x1 investor meetings
Presentation Date: Thursday, March 5

, 2026
Time: 8:00 AM EDT – 5:00 PM EDT

The Company will be available for one-on-one meetings at the conference. If interested, please contact your Centurion One Capital representative.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE

 NK cell engager platform. Our TriKE  platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE  technology. For more information, please visit  .

TriKE

is a registered trademark owned by GT Biopharma, Inc.

Corey Davis, Ph.D.